Vectura presents VR040 positive result in Parkinson's trial


Published 16 November 2010


Vectura Group has revealed positive data from a Phase II clinical study of its inhalation product, VR040, for the treatment of 'off' episodes (periods of inability to control movement) in patients with fluctuating Parkinson's disease.

VR040 is Vectura's proprietary formulation of apomorphine, delivered to the bloodstream by inhalation through the lungs using the company's proprietary dry powder inhalation (DPI) technology.
The results of the study demonstrate that VR040 improves the control of movement in patients with Parkinson's disease and VR040 produced clinically relevant and improvement, compared with placebo, of the Unified Parkinson's Disease Rating Scale Part III (UPDRS III), a measure of a patient's ability to control movement (see Notes for editors).
VR040 also reduced the time patients were in an 'off' state .....


http://drugdelivery.pharmaceutical-b...s-trial_161110